What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France

OBJECTIVES: New diagnostic criteria for Alzheimer’s disease (AD) include cerebrospinal fluid (CSF) biomarkers that allow diagnosis at the stage of mild cognitive impairment (MCI). However, the impact of CSF biomarkers in MCI populations in clinical practice has been poorly evaluated. The objective o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: Cognat, Emmanuel, Mouton Liger, François, Troussière, Anne-Cécile, Wallon, David, Dumurgier, Julien, Magnin, Eloi, Duron, Emmanuelle, Gabelle, Audrey, Croisile, Bernard, de la Sayette, Vincent, Jager, Alain, Blanc, Frederic, Bouaziz-Amar, Elodie, Miguet-Alfonsi, Carole, Quillard, Muriel, Schraen, Susanna, Philippi, Nathalie, Beaufils, Emilie, Pasquier, Florence, Hannequin, Didier, Robert, Philippe, Hugon, Jacques, Paquet, Claire
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Neurology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6549619/
https://ncbi.nlm.nih.gov/pubmed/31152032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2018-026380
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados